Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/34621
Tipo
ArtículoDerechos de autor
Acceso abierto
Fecha del embargo
2020-08-06
Colecciones
- INI - Artigos de Periódicos [3460]
Metadatos
Mostrar el registro completo del ítem
PROTECTOR EFFECT OF α-THALASSAEMIA ON CHOLECYSTITIS AND CHOLECYSTECTOMY IN SICKLE CELL DISEASE
Sickle cell disease
Cholelithiasis
Cholecystitis
Cholecystectomy
Multiplex-PCR
Autor
Afiliación
Rio de Janeiro Federal University. Faculty of Medicine. Clinical Medicine Postgraduate Program. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro Federal University. Faculty of Medicine. Institute of Paediatrics and Puericulture Martagão Gesteira. Department of Pediatrics. Rio de Janeiro, RJ, Brazil / Rio de Janeiro Federal University. Faculty of Medicine. Clinical Medicine Postgraduate Program. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro Federal University. Faculty of Medicine. Clinical Medicine Postgraduate Program. Rio de Janeiro, RJ, Brazil / Rio de Janeiro Federal University. School of Pharmacy. Department of Clinical Analysis and Toxicology. Rio de Janeiro, RJ, Brazil.
University of Rio de Janeiro. Pedro Ernesto Hospital. Internal Medicine Department. Hematology Service. Rio de Janeiro, RJ, Brazil.
University of Rio de Janeiro. Pedro Ernesto Hospital. Internal Medicine Department. Hematology Service. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro Federal University. Faculty of Medicine. Clinical Medicine Postgraduate Program. Rio de Janeiro, RJ, Brazil.
University of Rio de Janeiro. Pedro Ernesto Hospital. Internal Medicine Department. Hematology Service. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
National Institute of Cancer. Pharmacy Service. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro Federal University. Faculty of Medicine. Institute of Paediatrics and Puericulture Martagão Gesteira. Department of Pediatrics. Rio de Janeiro, RJ, Brazil / Rio de Janeiro Federal University. Faculty of Medicine. Clinical Medicine Postgraduate Program. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro Federal University. School of Pharmacy. Department of Clinical Analysis and Toxicology. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro Federal University. Faculty of Medicine. Institute of Paediatrics and Puericulture Martagão Gesteira. Department of Pediatrics. Rio de Janeiro, RJ, Brazil / Rio de Janeiro Federal University. Faculty of Medicine. Clinical Medicine Postgraduate Program. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro Federal University. Faculty of Medicine. Clinical Medicine Postgraduate Program. Rio de Janeiro, RJ, Brazil / Rio de Janeiro Federal University. School of Pharmacy. Department of Clinical Analysis and Toxicology. Rio de Janeiro, RJ, Brazil.
University of Rio de Janeiro. Pedro Ernesto Hospital. Internal Medicine Department. Hematology Service. Rio de Janeiro, RJ, Brazil.
University of Rio de Janeiro. Pedro Ernesto Hospital. Internal Medicine Department. Hematology Service. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro Federal University. Faculty of Medicine. Clinical Medicine Postgraduate Program. Rio de Janeiro, RJ, Brazil.
University of Rio de Janeiro. Pedro Ernesto Hospital. Internal Medicine Department. Hematology Service. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
National Institute of Cancer. Pharmacy Service. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro Federal University. Faculty of Medicine. Institute of Paediatrics and Puericulture Martagão Gesteira. Department of Pediatrics. Rio de Janeiro, RJ, Brazil / Rio de Janeiro Federal University. Faculty of Medicine. Clinical Medicine Postgraduate Program. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro Federal University. School of Pharmacy. Department of Clinical Analysis and Toxicology. Rio de Janeiro, RJ, Brazil.
Resumen en ingles
Objectives: Cholecystitis is one of the complications of symptomatic cholelithiasis responsible for high levels of morbidity of sickle cell disease (SCD) patients. Here, we investigated the possible protective role of single gene deletions of α-thalassaemia in the occurrence of cholelithiasis and cholecystitis in SCD patients, as well as the cholecystectomy requirements. Methods: The α-globin genotype was determined in 83 SCD patients using the multiplexpolymerase chain reaction and compared with clinical events. Results: Overall, in 23% of patients, -α3.7 deletion was found. α-Thalassaemia concomitant to SCD was an independent protective factor to cholecystitis (OR = 0.07; 95% CI: 0.01–0.66; p = 0.020) and cholecystectomy requirement (OR = 0.14; 95% CI: 0.03–0.60; p = 0.008). The risk of cholelithiasis was not affected by the α-thalassaemia concomitance. Conclusions: To the best our knowledge, our study is the first to show the protective effect of αthalassaemia on cholecystitis and cholecystectomy requirements in SCD, which may be due to an improved splenic function.
Palabras clave en ingles
α-thalassaemiaSickle cell disease
Cholelithiasis
Cholecystitis
Cholecystectomy
Multiplex-PCR
Compartir